Replies to post #5631 on GTC Biotherapeutics (fka GTCB)

[kris_kade]

If we don't find any insider buying at these levels, when will we ?

However the better side of me tells me something may be atworks...the street drives down the stock only to load up more pending news around the corner.

Hope we get some insider buying tomorrow..

[DewDiligence]

Re: ATryn launch in UK

Below is the text from the UK website [emphasis
added]. Note the average price of $22,600 per day.

>>
ATryn® (recombinant antithrombin) has been launched by LEO laboratories Ltd in the UK for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency. It is produced from goat’s milk that has a transgene for human antithrombin and offers an alternative to treatment with plasma-derived products.

ATryn is normally given in association with heparin or low molecular weight heparin and the therapeutic goal of treatment is to increase to, and maintain antithrombin activity between, 80 to 120% (0.8 – 1.2 IU/ml) for the duration of treatment. Initial treatment starts with a loading dose targeting an antithrombin activity level of 100%. This initial loading dose is based on body weight and on the pretreatment antithrombin activity level and is given as a 15 minute infusion immediately followed by initiation of the maintenance infusion.

The usual loading dose in surgical patients (baseline AT activity 50%, bodyweight 75 kg) with congenital antithrombin deficiency in clinical risk situations is 20-25 IU/kg and the usual maintenance dose is 4-5 IU/kg/h.

The cost of a pack of 10 x 1750 IU vials is £17,850. Based on the usual dosing (upper dosing range) described in the SPC for a 75 kg patient, the cost of treatment is approximately £11,000 [$22,600] per day.
<<